BB BIOTECH N Logo
CH0038389992
A0NFN3
BBZA.DE

BB BIOTECH N

Chargement des cours...

Prévisions

Aucune donnée d'analyste n'est disponible pour cette entreprise.

Discussions dans la communauté

  • Split BB Biotech 2016

    Rainer Rainer I dans Schnack

    0 3

  • BB Biotech makes twelve new investments after sale of Crinetics and Nuvalent

    BB Biotech realised about CHF 280 million in Q3 by selling Crinetics Pharmaceuticals and Nuvalent and immediately deployed the proceeds into twelve new positions. Larger purchases included Biogen, Incyte and Axsome Therapeutics; Alnylam was re-added to the portfolio after a price drop. Other new investments cover advanced development programmes such as Kodiak Sciences, Summit Therapeutics, LB Pharmaceuticals and Bicara, as well as smaller starter positions in Alto Neuroscience, Yarrow Bioscience and Eupraxia. Private holdings remain limited, while BB Biotech sees room to expand positions if clinical evidence is positive; the stock has picked up momentum again after a period of consolidation. » Plus sur deraktionaer.de


  • BB Biotech expands portfolio and adds twelve new positions

    BB Biotech expanded its portfolio by twelve new holdings in the third quarter and reinvested around CHF 280 million from takeovers. The new additions range from established biotech companies with product revenues to clinical-stage developers with upcoming milestones. The purchases aim to find stocks whose market valuations do not yet fully reflect their scientific, clinical and commercial potential. » Plus sur finanzen.net


  • BB Biotech posts profit again in third quarter and sees targeted investment opportunities

    BB Biotech recorded a profit of CHF 175 million in the third quarter, marking the second consecutive profitable quarter. The net asset value rose 5.6% in CHF during the quarter, and the company reports clinical and regulatory progress at portfolio companies. After the September correction, BB Biotech sees targeted buying opportunities in stocks whose prices have fallen despite unchanged clinical prospects; further milestones are expected in the fourth quarter. » Plus sur finanzen.net


  • BB Biotech: AI could trigger a new innovation-driven growth cycle in the biotech sector

    BB Biotech and Medpace are among the stocks traders are currently backing, as AI-supported models could accelerate drug development and spark broader innovation across the sector. After years dominated by GLP-1 and individual blockbusters, multiple biotech companies could now benefit from more efficient drug discovery and new discoveries. The article names three biotech stocks at 52-week highs that traders should keep an eye on. » Plus sur finanzen.net


  • BB Biotech: comeback gains momentum as analysts recommend selling numerous stocks

    Last trading week, numerous analysts advised exiting various stocks and issued multiple sell recommendations. At the same time, BB Biotech reported a stronger comeback with solid quarterly results and a portfolio that outperforms the industry index, while the stock still lags its intrinsic value. » Plus sur finanzen.net

En 2026, BB BIOTECH N a déjà versé 2,46 € de dividendes. Le dernier versement a eu lieu en mars.

Données financières de l'entreprise

Au dernier trimestre, BB BIOTECH N a réalisé un chiffre d'affaires de 99,79 M € et un bénéfice net de 184,91 M €
(EUR) septembre 2026
YoY
Chiffre d'affaires 99,79 M 343,70 %
Bénéfice brut 99,79 M 343,70 %
Bénéfice net 184,91 M 61,39 %
EBITDA 184,93 M 61,39 %

Données fondamentales

Indicateur Valeur
Capitalisation boursière
3,22 Md €
Nombre d'actions
55,15 M
Plus haut/bas sur 52 semaines
61,72 € - 44,45 €
Rendement du dividende
4,20 %
Dividendes TTM
2,46 €
Bêta
0,93
Ratio P/E
2,77
Ratio PEG
0,01
Ratio P/B
0,91
Ratio P/S
13,57

Profil de l'entreprise

BB Biotech AG est un fonds d'actions lancé et géré par Bellevue Asset Management AG. Le fonds investit sur les marchés actions cotés du monde entier. Il investit principalement dans les actions de sociétés actives dans les médicaments et les diagnostics fondés sur la biotechnologie moderne. Le fonds utilise une analyse fondamentale pour constituer son portefeuille. BB Biotech AG a été créée le 09 novembre 1993 et est domiciliée en Suisse.

Nom
BB BIOTECH N
PDG
Daniel Koller
Siège social Kusnacht,
Suisse
Site web
Secteur
Santé
Industrie
Biotechnologie
Introduction en bourse
04/01/2000
Employés 10

Symboles boursiers

Bourse Symbole
XETRA
BBZA.DE
SIX
BION.SW
Hamburg
BBZA.HM
London
0JYO.L
München
BBZA.MU
🍪

Parqet  utilise des cookies. En savoir plus